Prostate Cancer Clinical Trial
Official title:
An Open Phase II, Two-centre, 1-Arm Safety Study of Once-daily Orally Administered 10 mg ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer
This is a prospective, open, one-arm, two-centre, Phase II clinical safety pilot-study. The trial is designed to gain initial safety and efficacy-related data on once-daily orally administered ZD4054 10 mg in prior chemotherapy treated patients with metastatic hormone-resistant prostate cancer.
Study centres and number of patients planned This pilot study will be conducted in
approximately 24 patients recruited from two hospital-based Danish centres: department of
Urology K, Aarhus University Hospital, Skejby and department of Urologic Surgery D,
Rigshospitalet. The recruitment of patients will be competitive among centres. 1-2 months
before expected LSI it should be discussed if the target accrual should be expanded.
Study period Phase of development Estimated date of first patient enrolled August 1th 2009
II Estimated date of last patient completed July 31th 2012 Total study duration is
approximately 36 months, which includes 12 months' recruitment, 36-month follow-up for
safety and final survival analysis.
Objectives
The primary objective of this study is:
To assess the safety and tolerability profile of ZD4054 after treatment with chemotherapy
- Adverse events
- Vital signs
- Laboratory data
- ECGs
- Physical Exam
- Death from any cause
The secondary objectives of the study are:
1. To investigate the effect of ZD4054 on rate of rise of PSA
2. To investigate the effect of ZD4054 on prostate cancer related pain
3. To investigate the effect of ZD4054 on the plasma concentration of circulating tumour
cells (CTC).
In addition, Time to Progression and Overall Survival (time to death) will be compared with
historical data in a post chemotherapy population.
Study design This is a prospective, Open, One-arm, Phase II clinical safety pilot-study. The
trial is designed to gain initial safety and efficacy-related data on once-daily orally
administered ZD4054 10 mg in prior chemotherapy treated patients with metastatic
hormone-resistant prostate cancer.
Patients could receive other therapies including prednisolone, estramustine, ketoconazole
and second-line or third-line antiandrogens at investigator's discretion without being
considered treatment failures or having to stop study therapy; however every attempt will be
made to avoid changes in medication for at least 12 weeks to minimise potential for
confounding on study endpoints over this time period. Chemotherapy and radiation therapy may
also be administered in addition to study therapy at investigator's discretion after
objective progression if the patient is considered likely to derive benefit. Patients will
be followed to death.
Target patient population A total number of 24 male patients aged 18 years or older with
metastatic hormone-resistant prostate cancer who have progressive disease (defined by rising
serum prostate-specific antigen levels despite medical or surgical castration) and
previously received cytotoxic chemotherapy (docetaxel) for the treatment of HRPC.
Investigational product, dosage and mode of administration
Patients will not be randomised and all patients will receive:
• ZD4054 10 mg given orally, once daily in tablet form. Duration of treatment Patients will
receive daily ZD4054 as long as they meet no withdrawal criteria. Following completion of 24
months of ZD4054, patients, who in the investigator's opinion are experiencing benefit from
study treatment, may continue on ZD4054, for as long as they meet no withdrawal criteria.
Statistical methods The study is a pilot study designed to collect safety/tolerability data
and assess markers of efficacy. A total of 24 patients will be recruited into this pilot
study and this is based primarily on the number of patients that can be recruited in a
reasonable time period at the centres and should be sufficient to make an initial assessment
of safety/tolerability and the efficacy markers.
For the assessment of tolerability and safety, incidence and severity of adverse events
(AEs) (based on National Cancer Institute Common Terminology Criteria for Adverse Events,
version 3 (NCI CTCAE) grading), laboratory values, vital signs, ECGs and physical exam will
be summarised.
Secondary endpoints will be presented and analysed to investigate trends in the data. The
interpretation of the analyses will consider the number of assessments being undertaken.
Pain will be assessed using the Brief Pain Inventory Demography and baseline data will be
summarised. Any analyses will be performed using SPSS and other validated software as
appropriate.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |